NASDAQ:GALT Galectin Therapeutics Q2 2026 Earnings Results & Report $3.71 +0.07 (+1.92%) As of 10/15/2026 04:00 PM Eastern Galectin Therapeutics missed analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$0.14 versus the -$0.09 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeBefore Market OpensConference Call7:00 AM ET Galectin Therapeutics EPS ResultsActual EPS-$0.14Consensus EPS -$0.09Beat/MissMissed by -$0.05One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersGalectin Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsGalectin Therapeutics' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Galectin Therapeutics Q2 2026 Earnings FAQ Did Galectin Therapeutics beat earnings estimates for Q2 2026? Galectin Therapeutics (NASDAQ:GALT) reported earnings of -$0.14 per share for Q2 2026, missing the consensus estimate of -$0.09. The report was announced on Friday, August 14, 2026. When is Galectin Therapeutics' next earnings date? Galectin Therapeutics' next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Galectin Therapeutics on the company's earnings history page. Galectin Therapeutics Earnings HeadlinesGalectin Therapeutics (NASDAQ:GALT) Stock Crosses Above 200-Day Moving Average - Here's What HappenedOctober 8, 2026 | americanbankingnews.comGalectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is CriticalOctober 6, 2026 | seekingalpha.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026October 6, 2026 | globenewswire.comGalectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | globenewswire.comGalectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | globenewswire.comSee More Galectin Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Galectin Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galectin Therapeutics and other key companies, straight to your email. Email Address About Galectin TherapeuticsGalectin Therapeutics (NASDAQ:GALT) (NASDAQ:GALT) is a biotechnology company focused on developing therapies that target galectin-3, a protein believed to play a role in fibrosis, inflammation and cancer biology. The company’s research is aimed at addressing serious chronic diseases for which treatment options remain limited. Galectin Therapeutics’ lead investigational product is belapectin, also known as GR-MD-02. The drug is designed to inhibit galectin-3 and has been studied primarily in patients with advanced liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and portal hypertension. Belapectin is an investigational therapy and has not received regulatory approval. The company is also evaluating the potential use of galectin-3 inhibition in oncology, including as part of combination approaches intended to improve immune responses against cancer. Galectin Therapeutics was formerly known as Pro-Pharmaceuticals and adopted its current name in 2011. The company is headquartered in Norcross, Georgia, and conducts development activities through clinical research programs; specific commercial geographies are not applicable while its primary product remains investigational.View Galectin Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
